Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Should You Buy?

Key Points

• Lexeo shares rose 3.2% to $5.81 on Tuesday with volume about 58% below average; the company has a market cap of $430.5M, a negative PE of -2.65, and reported a narrower-than-expected loss of ($0.27) EPS for the quarter versus consensus ($0.32).
• Analysts are mixed but overall upbeat with a consensus rating of "Moderate Buy" and an average price target of $18.88, despite recent divergent notes (HC Wainwright cut its target to $10 while Chardan maintains a $17 target and Weiss Ratings stayed negative).
• The CEO sold 55,000 shares under a Rule 10b5-1 plan (reducing his stake by ~13.9%), even as institutional buying ramped up—Millennium and AQR materially increased positions—and institutional investors now own about 60.67% of the stock.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report)'s share price rose 3.2% during trading on Tuesday . The stock traded as high as $5.89 and last traded at $5.81. Approximately 438,089 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 1,038,026 shares. The stock had previously closed at $5.63.

Wall Street Analysts Forecast Growth

LXEO has been the subject of several analyst reports. HC Wainwright lowered their price objective on Lexeo Therapeutics from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, January 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Lexeo Therapeutics in a report on Friday, April 17th. Finally, Chardan Capital restated a "buy" rating and set a $17.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $18.88.

Lexeo Therapeutics Stock Up 3.2%

The company has a market capitalization of $430.46 million, a PE ratio of -2.65 and a beta of 1.99. The stock has a 50-day moving average of $6.31 and a 200 day moving average of $7.92.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. Equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.27 EPS for the current fiscal year.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares of the company's stock, valued at approximately $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,189 shares of company stock worth $397,156 over the last three months. Company insiders own 5.30% of the company's stock.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LXEO. AQR Capital Management LLC increased its position in shares of Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock valued at $175,000 after acquiring an additional 39,627 shares during the last quarter. Millennium Management LLC increased its position in shares of Lexeo Therapeutics by 654.8% during the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock valued at $3,718,000 after acquiring an additional 929,538 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Lexeo Therapeutics during the first quarter valued at approximately $85,000. Rhumbline Advisers increased its position in shares of Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company's stock valued at $105,000 after acquiring an additional 4,995 shares during the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics during the second quarter valued at approximately $50,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.